GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Beta

HighTide Therapeutics (HKSE:02511) Beta : N/A (As of May. 17, 2024)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-17), HighTide Therapeutics's Beta is Not available.


HighTide Therapeutics Beta Historical Data

The historical data trend for HighTide Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Beta Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Beta
- - -

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Beta - - - - -

Competitive Comparison of HighTide Therapeutics's Beta

For the Biotechnology subindustry, HighTide Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HighTide Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Beta falls into.



HighTide Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


HighTide Therapeutics  (HKSE:02511) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


HighTide Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


HighTide Therapeutics (HKSE:02511) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines